Topic: How To Invest

Hi Pat: I wonder what you think about Trimel Pharma. Thanks.

Article Excerpt

Trimel Pharmaceuticals, $0.69, symbol TRL on Toronto (Shares outstanding: 163.1 million; Market cap: $110.9 million; www.trimelpharmaceuticals.com), recently received approval from the U.S. Food and Drug Administration for its Natesto product (formerly called CompleoTRT). Natesto is a replacement therapy for men with conditions associated with low testosterone. The drug is self-administered through the nose. Current treatments for low testosterone include topical gels, patches placed on the skin or inside the mouth, injections and tablets. Low testosterone, also known as male hypogonadism, is a condition in which the testicles, hypothalamus or pituitary gland are affected by disease or damage that inhibits hormone and testosterone secretion. Signs and symptoms include erectile dysfunction, decreased sexual desire, fatigue, loss of energy, depressed mood and osteoporosis. Trimel also has a Phase II study underway for another drug, called Tefina, for treating female orgasmic disorder. This condition, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasms, leading to distress. There is not yet an approved…